A Two-Part Phase Ib/II Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous in Patients With Stage IV Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Atezolizumab; Bevacizumab; Carboplatin; Hyaluronidase; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Acronyms IMscin001
- Sponsors Roche
- 19 Jul 2019 Planned number of patients changed from 245 to 260.
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.
- 26 Nov 2018 Planned initiation date changed from 14 Nov 2018 to 28 Dec 2018.